Isoniazid-induced liver injury and immune response in mice

Journal of Immunotoxicology

Volumn 11, Issue 4, 2014, Pages 383-392

  Metushi, Imir G ^a   Uetrecht, Jack ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

Animal model; Drug induced liver injury; Idiosyncratic adverse drug reaction; Immunosuppression; Tolerance

Indexed keywords

CYTOKINE; INTERLEUKIN 12; INTERLEUKIN 1ALPHA; ISONIAZID; CBL PROTEIN; CBLB PROTEIN, MOUSE; INTERLEUKIN 1; PDCD1 PROTEIN, MOUSE; PROGRAMMED DEATH 1 RECEPTOR; SIGNAL TRANSDUCING ADAPTOR PROTEIN; TUBERCULOSTATIC AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; C57BL/6N MOUSE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG INDUCED DISEASE; ENZYME ASSAY; FEMALE; FOOD INTAKE; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOHISTOCHEMISTRY; LIVER FUNCTION TEST; LIVER HISTOLOGY; LIVER INJURY; MALE; MOUSE; NONHUMAN; TOXIC HEPATITIS; WESTERN BLOTTING; ADAPTIVE IMMUNITY; ANIMAL; C57BL MOUSE; DISEASE MODEL; DRUG EFFECTS; GENETICS; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOLOGY; INNATE IMMUNITY; KNOCKOUT MOUSE; METABOLISM; RAT;

ANIMALIA; MUS;

ADAPTIVE IMMUNITY; ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANIMALS; ANTITUBERCULAR AGENTS; DISEASE MODELS, ANIMAL; DRUG-INDUCED LIVER INJURY; HUMANS; IMMUNE TOLERANCE; IMMUNITY, INNATE; INTERLEUKIN-1; INTERLEUKIN-12; ISONIAZID; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; PROGRAMMED CELL DEATH 1 RECEPTOR; PROTO-ONCOGENE PROTEINS C-CBL; RATS;

EID: 84911465513     PISSN: 1547691X     EISSN: 15476901     Source Type: Journal    
DOI: 10.3109/1547691X.2013.860644     Document Type: Article

References (32)

1. Black, M., Mitchell, J. R., Zimmerman, H. J., et al. 1975. Isoniazidassociated hepatitis in 114 patients. Gastroenterology 69:289-302
2. Blair, I. A., Mansilla Tinoco, R., Brodie, M. J., et al. 1985. Plasma hydrazine concentrations in man after isoniazid and hydralazine administration. Human Toxicol. 4:195-202
3. Centers for Disease Control and Prevention (CDC) 2010. Severe isoniazid-Associated liver injuries among persons being treated for latent tuberculosis infection -United States, 2004-2008. MMWR 59: 224-229
4. Crispe, I. N., Dao, T., Klugewitz, K., et al. 2000. The liver as a site of T-cell apoptosis: Graveyard, or killing field?. Immunol. Rev. 174: 47-62
5. De Boer, L. C., Steerenberg, P. A., Van Der Meijden, P. M., et al. 1992. Impaired immune response by isoniazid treatment during intra-vesical BCG administration in the guinea pig. J. Urol. 148:1577-1582
6. Fukino, K., Sasaki, Y., Hirai, S., et al. 2008. Effects of N-Acetyltransferase 2 (NAT2), CYP2E1, and glutathione-S-transferase (GST) genotypes on serum concentrations of isoniazid and metabolites in tuberculosis patients. Toxicol. Sci. 33:187-195
7. Gent, W. L., Seifart, H. I., Parkin, D. P., et al. 1992. Factors in hydrazine formation from isoniazid by paediatric and adult tuberculosis patients. Eur. J. Clin. Pharmacol. 43:131-136
8. Huang, Y. S., Chern, H. D., Su, W. J., et al. 2002. Polymorphism of the N-Acetyltransferase 2 gene as a susceptibility risk factor for antituberculosis drug-induced hepatitis. Hepatology 35:883-889
9. Jones, S. A., Moore, L. B., Shenk, J. L., et al. 2000. The pregnane X receptor: A promiscuous xenobiotic receptor that has diverged during evolution. Mol. Endocrinol. 14:27-39
10. Laskin, D. L. 2009. Macrophages and inflammatory mediators in chemical toxicity: A battle of forces. Chem. Res. Toxicol. 22: 1376-1385
11. Lehmann, J. M., McKee, D. D., Watson, M. A., et al. 1998. The human orphan nuclear receptor PXR is activated by compounds that regulate CYP3A4 gene expression and cause drug interactions. J. Clin. Invest. 102:1016-1023
12. Maddrey, W. C., and Boitnott, J. K. 1973. Isoniazid hepatitis. Ann. Int. Med. 79:1-12
13. Metushi, I. G., Cai, P., Zhu, X., et al. 2011. A fresh look at the mechanism of isoniazid-induced hepatotoxicity. Clin. Pharmacol. Ther. 89: 911-914
14. Metushi, I. G., Nakagawa, T., and Uetrecht, J. 2012. Direct oxidation and covalent binding of isoniazid to rodent liver and human hepatic microsomes: Humans are more like mice than rats. Chem. Res. Toxicol. 25:2567-2576
15. Metushi, I. G., Sanders, C., Lee, W. M., and Uetrecht, J. 2013. Detection of anti-isoniazid and anti-cyp antibodies in patients with isoniazidinduced liver failure. Hepatology (Epub ahead of print)
16. Mitchell, J. R., Zimmerman, H. J., Ishak, K. G., et al 1976. Isoniazid liver injury: Clinical spectrum, pathology, and probable pathogenesis. Ann. Int. Med. 84:181-192
17. Naisbitt, D. J., Gordon, S. F., Pirmohamed, M., and Park, B. K. 2000. Immunological principles of adverse drug reactions: The initiation and propagation of immune responses elicited by drug treatment. Drug Safety 23:483-507
18. Noda, A., Hsu, K. Y., Noda, H., et al. 1983. Is isoniazid-hepatotoxicity induced by the metabolite, hydrazine?. J. UOEH 5:183-190
19. Onizuka, S., Tawara, I., Shimizu, J., et al. 1999. Tumor rejection by in vivo administration of anti-CD25 (IL-2Ra) monoclonal antibody. Cancer Res. 59:3128-3133
20. Pardoll, D. M. 2012. The blockaDe of immune checkpoints in cancer immunotherapy. Nat. Rev. Cancer 12:252-264
21. Quintana, F. J., Basso, A. S., Iglesias, A. H., et al. 2008. Control of Treg and TH17 cell differentiation by the aryl hydrocarbon receptor. Nature 453:65-71
22. Salazar-Paramo, M., Rubin, R. L., and Garcia De la Torre, I. 1992. Systemic lupus erythematosus induced by isoniazid. Ann. Rheum. Dis. 51:1085-1087
23. Sarich, T. C., Youseffi, M., Zhou, T., et al. 1996. Role of hydrazine in the mechanism of isoniazid hepatotoxicity in rabbits. Arch. Toxicol. 70: 835-840
24. Sharma, S. K., Balamurugan, A., Saha, P. K., et al. 2002. Evaluation of clinical and immunogenetic risk factors for the development of hepatotoxicity during anti-tuber-culosis treatment. Am. J. Resp. Crit. Care Med. 166:916-919
25. Soyer, O. U., Akdis, M., Ring, J., et al. 2013. Mechanisms of peripheral tolerance to allergens. Allergy 68:161-170
26. Stassar, M. J., Vegt, P. D., Steerenberg, P. A., et al. 1994. Effects of isoniazid (INH) on the BCG-induced local immune response after intra-vesical BCG therapy for superficial bladder cancer. Urol. Res. 22: 177-184
27. Tiegs, G., and Lohse, A. W. 2010. Immune tolerance: What is unique about the liver?. J. Autoimmun. 34:1-6
28. Venuprasad, K. 2010. Cbl-b and itch: Key regulators of peripheral T-cell tolerance. Cancer Res. 70:3009-3012
29. Warrington, R. J., McPhillips-Feener, S., and Rutherford, W. J. 1982. The predictive value of the lymphocyte transformation test in isoniazidassociated hepatitis. Clin. Allergy 12:217-222
30. Warrington, R. J., Tse, K. S., Gorski, B. A., et al. 1978. Evaluation of isoniazid-Associated hepatitis by immunological tests. Clin. Exp. Immunol. 32:97-104
31. Whitehouse, L. W., Tryphonas, L., Paul, C. J., et al. 1983. Isoniazidinduced hepatic steatosis in rabbits: An explanation for susceptibility and its antagonism by pyridoxine hydrochloride. Can. J. Physiol. Pharmacol. 61:478-487
32. Zimmerman, H. J. (Ed.). 1999. Hepatotoxicity: The Adverse Effects of Drugs and Other Chemicals on the Liver. Philadelphia, PA: Lippincott Williams & Wilkins.